About CREON

CREON brings a legacy of leadership to the table

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.1

CREON® (pancrelipase) 1236 Delayed-Release Capsules

Capsules shown are not actual size and do not represent the exact color shade. For illustrative purposes only. The active ingredient in CREON evaluated in clinical trials is lipase.

  • CREON was the first pancreatic enzyme replacement therapy (PERT) to receive FDA approval2
  • CREON is the #1 prescribed PERT3
  • CREON was the first PERT with dosing for patients with EPI due to CP or pancreatectomy1,4
  • Unrestricted access (no prior authorization) for 94% of insured patients5*†
  • Lowest branded co-pay for 96% of insured patients5*†
  • Medicare Part D coverage for more patients than any other pancreatic enzyme replacement therapy5

*Insured patients = Commercial, Medicare Part D, and Managed Medicaid (excludes TRICARE and fee for service).

†Formulary definitions: "Unrestricted" implies no step edit, prior authorization, quantity limits, or age restrictions. “Lowest branded co-pay” means the product is in the formulary tier status designated by the insurer as the lowest branded co-pay in the therapeutic class.

Learn how CREON® (pancrelipase) works

How does CREON work?

Learn More
CREON® (pancrelipase) is offered in different dosages, depending on a variety of factors

CREON offers a wide range of dosing strengths

See Dosing Strengths
Use the dosing calculator to help determine the proper dosage of CREON® (pancrelipase)

Determine an appropriate per-meal dose for your patients

Use Dosing Guide

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. References:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.
  3. Food and Drug Administration. US Department of Health and Human Services. NDA 20-725. April 30, 2009. http://www.accessdata.fda.gov​/drugsatfda_docs​/appletter​/2009​/020725s000ltr.pdf. Accessed February 15, 2018.
  4. IMS Health, IMS National Prescription Audit, February 2018.
  5. Food and Drug Administration. US Department of Health and Human Services. NDA 020725/S-003. April 30, 2010. http://www.accessdata.fda.gov​/drugsatfda_docs​/appletter​/2010​/020725s003ltr.pdf. Accessed February 15, 2018.
  6. Data on file. North Chicago, IL: AbbVie, Inc. Source: Business One Technologies. November 2017.

back to top #tbd